Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics.

Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
02 May 2019
Historique:
entrez: 4 5 2019
pubmed: 3 5 2019
medline: 3 5 2019
Statut: epublish

Résumé

One of the funding sources (FEDER-Unión Europea) was not previously acknowledged in this Article. This study was supported by the Spanish Ministry of Health, Instituto de Salud Carlos III (FIS, Fondo de Investigacion Sanitaria PI13/00812, PI16/0122) and FEDER-Unión Europea.

Identifiants

DOI: 10.1038/s41398-019-0480-z PMID: 31048679 PMC: PMC6497654
pubmed: 31048679
doi: 10.1038/s41398-019-0480-z
pii: 10.1038/s41398-019-0480-z
pmc: PMC6497654
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

145

Commentaires et corrections

Type : ErratumFor

Auteurs

Daniel Boloc (D)

Department of Medicine, University of Barcelona, Barcelona, Spain.

Anna Gortat (A)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.

Jia Qi Cheng-Zhang (JQ)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.

Susana García-Cerro (S)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.

Natalia Rodríguez (N)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.

Mara Parellada (M)

Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Barcelona, Spain.
Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain.

Jeronimo Saiz-Ruiz (J)

Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Barcelona, Spain.
Hospital Ramon y Cajal, Universidad de Alcala, IRYCIS, Madrid, Spain.

Manolo J Cuesta (MJ)

Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Barcelona, Spain.
Department of Psychiatry, Complejo Hospitalario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

Patricia Gassó (P)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.

Amalia Lafuente (A)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Barcelona, Spain.
The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.

Miquel Bernardo (M)

Department of Medicine, University of Barcelona, Barcelona, Spain. bernardo@clinic.ub.es.
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Barcelona, Spain. bernardo@clinic.ub.es.
The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. bernardo@clinic.ub.es.
Barcelona Clínic Schizophrenia Unit, Hospital Clínic de Barcelona, Barcelona, Spain. bernardo@clinic.ub.es.

Sergi Mas (S)

Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain. sergimash@ub.edu.
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Carlos III Health Institute, Barcelona, Spain. sergimash@ub.edu.
The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. sergimash@ub.edu.
ORCID: 0000-0003-3336-6298

Classifications MeSH